FRANCISCO ANTONIO
GÓMEZ VEIGA
Investigador en el periodo 2014-2021
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (32)
2022
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282
-
Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Journal of Clinical Oncology, Vol. 37
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups
Prostate, Vol. 82, Núm. 13, pp. 1237-1247
2021
-
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
The Journal of urology, Vol. 205, Núm. 5, pp. 1361-1371
-
Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys
Value in Health, Vol. 24, Núm. 11, pp. 1676-1685
-
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
Targeted Oncology, Vol. 16, Núm. 3, pp. 357-367
-
Reply by Authors
The Journal of urology, Vol. 205, Núm. 5, pp. 1371
2020
-
Advances in urologic oncology “OncoForum”: The best of 2019
Actas Urologicas Espanolas, Vol. 44, Núm. 9, pp. 586-596
-
Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry
Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 156-163
-
Efficacité de l’enzalutamide (ENZA) + traitement par suppression androgénique (TSA) dans le cancer de la prostate hormonosensible métastatique (mHSPC) en fonction de la localisation des métastases : analyses post-hoc de l’étude ARCHES
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 745
-
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
Targeted Oncology, Vol. 15, Núm. 3, pp. 301-315
-
The impact of time from biopsy to radical prostatectomy on Gleason score undergrading and other related factors
Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 187-195
2019
-
Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain
Actas Urologicas Espanolas, Vol. 43, Núm. 10, pp. 562-567
-
Three-year interim results of overall and progression-free survival in a cohort of patients with prostate cancer (GESCAP group)
Actas Urologicas Espanolas, Vol. 43, Núm. 1, pp. 4-11
2018
-
Cáncer de próstata avanzado y calidad de vida
Archivos Espanoles de Urologia, Vol. 71, Núm. 3, pp. 306-314
-
Developments in urologic oncology “OncoForum”: The best of 2017
Actas Urologicas Espanolas
-
Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity
Actas Urologicas Espanolas
2017
-
A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients
Clinical and Translational Oncology, Vol. 19, Núm. 11, pp. 1350-1357
-
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study
Journal of Urology, Vol. 198, Núm. 5, pp. 1054-1060
-
Consenso sobre el manejo del cáncer de próstata resistente a la castración avanzado en España
Archivos Espanoles de Urologia, Vol. 70, Núm. 9, pp. 777-791